Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.

The Journal of Urology
H Barton GrossmanMaximilian Burger

Abstract

We assessed the impact of hexaminolevulinate fluorescence cystoscopic detection of papillary, nonmuscle invasive bladder cancer on the long-term recurrence rate. Long-term followup was assessed in 551 participants enrolled in a prospective, randomized study of fluorescence cystoscopy for Ta or T1 urothelial bladder cancer. In the original study 280 patients in the white light cystoscopy group and 271 in the fluorescence cystoscopy group were followed with cystoscopy for 3, 6 and 9 months after initial resection or until recurrence. A study extension protocol was done for long-term followup of these patients. Followup information was obtained for 261 of the 280 patients (93%) in the white light group and 255 of the 271 (94%) in the fluorescence group. Median followup in the white light and fluorescence groups was 53.0 and 55.1 months, and 83 (31.8%) and 97 patients (38%) remained tumor free, respectively. Median time to recurrence was 9.4 months in the white light group and 16.4 months in the fluorescence group (p = 0.04). The intravesical therapy rate was similar in the 2 groups (46% and 45%, respectively). Cystectomy was done in 22 of 280 cases (7.9%) in the white light group and in 13 of the 271 (4.8%) in the fluorescence gro...Continue Reading

References

Dec 11, 2003·The Journal of Urology·Jörg SchmidbauerUNKNOWN Hexvix PCB301/01 Study Group
Mar 31, 2009·Scandinavian Journal of Urology and Nephrology·Per-Uno MalmströmJim Furniss
Sep 21, 2010·The Journal of Urology·Gary D Steinberg

❮ Previous
Next ❯

Citations

Mar 14, 2013·Der Urologe. Ausg. A·A KarlD Zaak
Jan 24, 2013·Current Urology Reports·Roman Mayr, Maximilian Burger
Jul 1, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·D CharbitC Pfister
Mar 25, 2014·Current Urology Reports·Aristeo Lopez, Joseph C Liao
Jan 30, 2014·European Urology·Robert S SvatekYair Lotan
Oct 31, 2014·Science Translational Medicine·Ying PanJoseph C Liao
Aug 21, 2013·Expert Opinion on Biological Therapy·Anna V van Lingen, J Alfred Witjes
Jul 6, 2013·European Urology·Marko BabjukUNKNOWN European Association of Urology
Apr 2, 2013·The Urologic Clinics of North America·Chad R RitchTodd M Morgan
Apr 2, 2013·The Urologic Clinics of North America·Joseph A Gillespie, Michael A O'Donnell
Sep 18, 2012·European Urology·Maximilian BurgerUNKNOWN International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012
Jan 18, 2015·World Journal of Urology·Georgios GakisArnulf Stenzl
Aug 19, 2014·Cancer·Seth P Lerner, Alvin Goh
May 6, 2015·Urologic Oncology·Yair Lotan
Apr 18, 2015·The Urologic Clinics of North America·David C JohnsonMatthew E Nielsen
Nov 24, 2016·Postgraduate Medical Journal·Michele TonuttiMikael H Sodergren
May 5, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Thorsten H EckeHolger Gerullis
Jul 6, 2014·Current Opinion in Urology·Shahrokh F Shariat
Dec 13, 2016·Current Opinion in Urology·Esmee Iml Liem, Theo M de Reijke
Feb 4, 2014·Therapeutic Advances in Urology·Puck Oude Elferink, J Alfred Witjes
Apr 6, 2013·Urologia·Vittorino MontanaroVincenzo Altieri
Jul 13, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Yasushi NakaiKiyohide Fujimoto
Oct 30, 2018·British Medical Bulletin·Simon J Crabb, James Douglas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.